Scott Stone, MD
Medical Oncology · Plano, TXNPI 1467494690
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,386 of the $11,747 with a category attached, or 62.9%. It is spread thinly across 60 manufacturers, the largest accounting for just 17.0%. 2025 is the largest year on record at $3,454, more than ten times the $134 reported in 2019.
Across 333 payments — averaging $35.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- AstraZeneca$1K
- Deciphera Pharmaceuticals Inc.$1K
- Johnson & Johnson$603
- Merck$561
- Novartis$560
- plus $6K from 54 others
Across 108 payments — averaging $1718.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$92K
- Janssen Research & Development, LLC$37K
- GSK$15K
- Morphosys AG$15K
- Karyopharm Therapeutics Inc.$14K
- Bristol Myers Squibb$11K
- plus $762 from 2 others
What the payments were for
- Consulting fees$2,90025%
- Speaking & faculty fees$1,40012%
- Food & beverage$7,38663%
- Education$611%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,747 in reported general payments places this provider in the 65th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 43 | $744,337 |
| JakafiRuxolitinib Phosphate | 28 | $454,793 |
| BrukinsaZanubrutinib | 23 | $333,612 |
| VerzenioAbemaciclib | 20 | $304,410 |
| LonsurfTrifluridine/Tipiracil Hcl | 12 | $190,787 |
| CalquenceAcalabrutinib Maleate | 11 | $172,249 |
| Imatinib Mesylate | 38 | $164,028 |
| XareltoRivaroxaban | 45 | $66,928 |
| EliquisApixaban | 60 | $52,934 |
| VenclextaVenetoclax | 20 | $35,221 |
| GleevecImatinib Mesylate | 12 | $29,625 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 45 | $1,285 |
| Fentanyl | 11 | $1,196 |
| Hydroxyurea | 50 | $1,176 |
| Anastrozole | 90 | $974 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $153 | $744,33743 claims |
| Incyte CorporationJakafi | $122 | $454,79328 claims |
| Beigene USA, Inc.Brukinsa | $87 | $333,61223 claims |
| Lilly USA, LLCVerzenio, Olanzapine | $25 | $304,46953 claims |
| Taiho Oncology, Inc.Lonsurf | $20 | $190,78712 claims |
| AstraZenecaCalquence | $1,288 | $172,24911 claims |
| Johnson & JohnsonXarelto | $603 | $66,92845 claims |
| PfizerEliquis | $276 | $52,93460 claims |
| AbbVieVenclexta | $296 | $35,22120 claims |
| NovartisGleevec | $560 | $29,62512 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $2,000 | $44833 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 495 medical oncology providers in Texas.
Other medical oncology in Plano
- Moshe LevyDallas$5.1M
- Suresh RatnamMcAllen$3M
- Roy HerbstHouston$1.9M
- Andrew WhiteleyDallas$1.7M
- Eric NadlerDallas$1.6M
- Vijay GunugantiSan Antonio$1.5M
- Sue EckhardtAustin$1.5M
- Joyce O'ShaughnessyDallas$1.3M
- Ronan KellyDallas$1.1M
- Maen AbdelrahimHouston$999K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.